SCHEMBL4707150

SCHEMBL4707150

CC(=O)c1c(-c2ccccc2)nn(Cc2ccccc2)c(=O)c1Nc1cccc(Cl)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.57
PARP1 P09874 2/20 0.51
ACHE P22303 1/20 0.49
BACE1 P56817 1/20 0.49
MAPT P10636 5/20 0.47
TP53 P04637 1/20 0.47
KCNJ6 P48051 2/20 0.46
KCNJ5 P48544 2/20 0.46
KCNJ3 P48549 2/20 0.46
ALDH1A1 P00352 3/20 0.45
NPSR1 Q6W5P4 3/20 0.44
LMNA P02545 2/20 0.44
HTT P42858 2/20 0.44
GAA P10253 1/20 0.44
MAPK1 P28482 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4707420 0.94 PDE4B (0.54) PDE4BPARP1ACHEBACE1MAPT
SCHEMBL4058811 0.91 PDE4B (0.70) PDE4BPARP1ACHEBACE1MAPT
SCHEMBL4706453 0.89 PDE4B (0.56) PDE4BPARP1ACHEBACE1MAPT
SCHEMBL4706078 0.89 PDE4B (0.56) PDE4BKCNJ6KCNJ5KCNJ3ALDH1A1
SCHEMBL4707438 0.89 PDE4B (0.59) PDE4BPARP1ACHEBACE1MAPT
SCHEMBL4708339 0.87 PDE4B (0.57) PDE4BPARP1ACHEBACE1MAPT
SCHEMBL4708038 0.87 PDE4B (0.54) PDE4BPARP1ACHEBACE1MAPT
SCHEMBL4707055 0.87 PDE4B (0.54) PDE4BPARP1ACHEBACE1MAPT
SCHEMBL4707865 0.86 PDE4B (0.62) PDE4BPARP1ACHEBACE1MAPT
SCHEMBL4707251 0.85 MAPT (0.55) PDE4BPARP1ACHEBACE1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459453-B2 Pyridazin-3(2H)-one derivatives as PDE4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2008-12-02 US claimed
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2006-03-09 US claimed
US-7459453-B2 Pyridazin-3(2H)-one derivatives as PDE4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2008-12-02 US disclosed
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS DAL PIAZ VITTORIO 2008-10-30 US disclosed
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2006-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS PDE4A, PDE3A, PDE4B PDE4B 3/4885PARP1 1082/4885ACHE 51/4885
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors PDE4A, PDE3A, PDE4B PDE4B 3/4885PARP1 1082/4885ACHE 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.